Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)resistant chronic hepatitis B virus (HBV) infections. We evaluated the efficacy of ETV in patients who were resistant to lamivudine (LAM)/ADV sequential therapy and in those resistant to LAM monotherapy. Fifty LAM/
Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance
β Scribed by Nao Kurashige; Kazuyoshi Ohkawa; Naoki Hiramatsu; Takayuki Yakushijin; Kiyoshi Mochizuki; Tsugiko Oze; Shinichi Kiso; Tatsuya Kanto; Tetsuo Takehara; Akinori Kasahara; Yoshinori Doi; Akira Yamada; Kazuto Fukuda; Masahide Oshita; Eiji Mita; Hiroyuki Fukui; Toshihiko Nagase; Harumasa Yoshihara; Yasuharu Imai; Michio Kato; Takeshi Kashihara; Norio Hayashi
- Book ID
- 106180503
- Publisher
- Springer Japan
- Year
- 2009
- Tongue
- English
- Weight
- 239 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0944-1174
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract No study has reported on the comparative effect of adefovir (ADV) addβon lamivudine (LAM) versus switching to entecavir (ETV) in LAMβresistant patients with chronic hepatitis B. From October 2007 to September 2008, 92 consecutive LAMβresistant patients were enrolled (47 LAMβ+βADV and 45